Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases.

Preeti Kanikarla MarieCara L Haymaker Edwin Roger Parra Cuentes Young Uk KimRossana LazcanoSwati GiteDaniele LorenziniIgnacio I WistubaRebecca S Slack TidwellXiaofei SongWai Chin Foo Dipen Maheshbhai MaruYun Shin ChunAndy FutrealBryan KeeDavid MenterLuisa Maren Solis Soto Ching-Wei D Tzeng Christine M ParseghianKanwal RaghavVan Karlyle Morris Chia-Chi ChangRobert JenqAlda L Tam Chantale BernatchezScott KopetzJean-Nicholas Vauthey Michael James Overman

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

This study demonstrates the safety of neoadjuvant combination tremelimumab and durvalumab prior to colorectal cancer liver resection. Evidence for T- and B-cell activation following this therapy was seen in pMMR metastatic colorectal cancer.

Keyphrases

liver metastases
metastatic colorectal cancer
clinical trial
locally advanced
study protocol
rectal cancer
patients undergoing
lymph node
cardiac surgery
squamous cell carcinoma
open label
combination therapy
replacement therapy
mesenchymal stem cells
bone marrow
cell therapy